Efficacy and Safety of Subcutaneous Vedolizumab in Patients With Moderately to Severely Active Crohn’s Disease: Results From the VISIBLE 2 Randomised Trial

2021163 citationsJournal Articlehybrid Open Access

Authors

Séverine Vermeire · KU Leuven

Geert D’Haens · Amsterdam University Medical Centers

Filip Baert · AZ Delta

Silvio Danese · Istituti di Ricovero e Cura a Carattere Scientifico

Taku Kobayashi · Kitasato University

Edward V. Loftus · Mayo Clinic in Arizona

Siddharth Bhatia ·

Abstract

Vedolizumab SC is an effective and safe maintenance therapy in patients with CD who responded to two infusions of vedolizumab intravenous induction therapy.

Topics & Keywords

Inflammatory Bowel Disease Microscopic Colitis Eosinophilic Esophagitis

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of Crohn s and Colitis

Volume 16, Issue 1, pp. 27-38

DOI: 10.1093/ecco-jcc/jjab133

Field-Weighted Citation Impact: 20.95